Incyte (INCY) Q2 Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs
July 31, 2018 7:00 AM EDTTotal product-related revenues of $421 million in Q2 2018, representing 29 percent growth over the same period last year; Jakafi® (ruxolitinib) revenues of $346 million in Q2 2018, representing 25 percent growth over the same period last year Pivotal REACH1 study of Jakafi in steroid-refractory acute GVHD met primary endpoint; sNDA submission expected in Q3 2018 Later-stage portfolio provides potential for accelerated growth from multiple near-to-market opportunities
Second Quarter Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte... More
